deltatrials
Completed PHASE3 NCT00130975

Candesartan in the Prevention of Relapsing Atrial Fibrillation

Sponsor: Asker & Baerum Hospital

Conditions Atrial Fibrillation
Interventions Candesartan
Updated 5 times since 2017 Last updated: Jan 3, 2007 Started: Apr 30, 2001 Completion: Sep 30, 2005

A PHASE3 clinical study on Atrial Fibrillation, this trial is completed. The trial is conducted by Asker & Baerum Hospital and has accumulated 5 data snapshots since 2001. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Asker & Baerum Hospital
  • AstraZeneca
  • Helse Ost
  • Ullevaal University Hospital
Data source: Asker & Baerum Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Oslo, Norway
  • • Rud, Norway